

Nectar Lifesciences Ltd.



Ref No. NLL/CS/2014- 475

Dated: 11.02.2014

1. National Stock Exchange of India Limited
'G' Block, Exchange Plaza, Bandra Kurla Complex,
Bandra (East), MUMBAI – 400 051.
2. Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers, Dalal Street,
MUMBAI – 400 001.

Sub: Compliance under Clause 41 the Listing Agreement.

Sirs,

Pursuant to Clause 41 of the Listing Agreement, please find enclosed herewith a copy of the Unaudited Financial Results for the period ended on December 31, 2013, as approved by the Board of Directors in their meeting held on even date i.e. February 11, 2014.

Kindly take the same on record and oblige.

Thanking you,

Yours truly,

For NECTAR LIFESCIENCES LIMITED


Sundar Lal
Company Secretary

Encl. as above

CC: - Societe de la Bourse de Luxembourg S.A.
BP 165, L-2011 Luxembourg,
Telephone : (00352) 47 79 38-1
Fax: (00352) 47 32 98



NECTAR LIFESCIENCES LIMITED

Regd. Office: Vill. Saidpura, Tehsil Dorabassi, Distt. Mohali, (Punjab)

Statement of Unaudited Financial Results for the Quarter and Nine Months ended 31.12.2013 (Rs in Lacs)

S. No	PARTICULARS	Quarter ended 31-12-2013	Quarter ended 30-09-2013	Quarter ended 31-12-2012	9 Month ended 31-12-2013	9 Month ended 31-12-2012	Year ended 31-03-2013
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	Income from Operations						
	(a) Gross Sales	40700.32	45749.04	38095.64	122600.30	129091.37	167324.71
	Less : Excise Duty	1596.41	1597.38	1207.10	4863.47	3373.80	4843.28
	Net Sales	39103.91	44151.66	36888.54	117736.83	125717.57	162481.43
	(b) Other Operating Income	6.80	6.89	18.85	20.22	133.47	143.67
	Total Income from Operations (net)	39110.71	44158.55	36907.39	117757.05	125851.04	162625.10
2.	Expenses						
	(a) Cost of Materials consumed	24867.91	31105.68	30121.56	80541.43	91328.65	114652.24
	(b) Purchase of Stock in Trade	577.99	520.22	845.34	3835.16	5335.82	5999.80
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	568.14	(810.18)	(6041.24)	(3190.55)	(4892.21)	(6440.21)
	(d) Employee benefits expense	1303.99	1256.49	1137.20	3959.18	3362.19	4861.11
	(e) Depreciation and amortisation expense	2104.07	2098.93	1922.39	6342.51	5634.58	7595.61
	(f) Other expenses	3841.16	4443.18	3649.36	11209.28	10384.16	14544.16
	Total Expenses	33263.26	38614.32	31634.61	102697.01	111153.19	141212.70
3.	Profit from Operations before Other Income, finance costs and exceptional items (1-2)	5847.45	5544.23	5272.78	15060.04	14697.85	21412.40
4.	Other Income	244.40	429.04	412.72	1072.30	1237.42	1604.03
5.	Profit before finance costs and exceptional items (3+4)	6091.85	5973.27	5685.50	16132.34	15935.27	23016.43
6.	Finance costs	3983.04	3941.79	2817.41	10501.61	8078.09	11548.93
7.	Profit after finance costs but before exceptional items (5-6)	2108.81	2031.48	2868.09	5630.73	7857.18	11467.50
8.	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
9.	Profit from ordinary activities before tax (7+8)	2108.81	2031.48	2868.09	5630.73	7857.18	11467.50
10.	Tax Expense	395.75	513.83	723.46	1292.40	1854.84	2900.95
11.	Net Profit from ordinary activities after tax (9-10)	1713.06	1517.65	2144.63	4338.33	6002.34	8566.55
12.	Extraordinary item (net of tax expense)	0.00	0.00	0.00	0.00	0.00	0.00
13.	Net Profit for the period (11-12)	1713.06	1517.65	2144.63	4338.33	6002.34	8566.55
14.	Paid up Equity Share Capital (Face Value per share : Re.1/-)	2,242.61	2,242.61	2,242.61	2,242.61	2,242.61	2,242.61
15.	Reserves excluding Revaluation Reserves	-	-	-	-	-	84,517.96
16.i	Earnings per Share (EPS) (before extraordinary items)						
	a) Basic	0.76	0.68	0.96	1.93	2.68	3.82
	b) Diluted	0.76	0.68	0.96	1.93	2.68	3.82
16.ii	Earnings per Share (EPS) (after extraordinary items)						
	a) Basic	0.76	0.68	0.96	1.93	2.68	3.82
	b) Diluted	0.76	0.68	0.96	1.93	2.68	3.82

Part II Select Information for the Quarter and nine month ended 31.12.2013

A Particulars of shareholding							
1.	Public Shareholding						
	- Number of Shares	124,792,970	124,792,970	124,792,970	124,792,970	124,792,970	124,792,970
	- Percentage of Shareholding	55.65	55.65	55.65	55.65	55.65	55.65
2.	Promoters and Promoter Group Shareholding						
	a) Pledged/Encumbered						
	- Number of Shares	-	-	-	-	-	-
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
	- Percentage of Shares (as a % of the total share capital of the company)	-	-	-	-	-	-
	b) Non-encumbered						
	- Number of Shares	99,468,000	99,468,000	99,468,000	99,468,000	99,468,000	99,468,000
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the company)	44.35	44.35	44.35	44.35	44.35	44.35
B	Investor Complaints	3 Months ended 31.12.2013					
	Pending at the beginning of Quarter	-					
	Received During the Quarter	15					
	Disposed Off During the Quarter	15					
	Pending at the end of Quarter	-					

Notes:

- The above financial results were reviewed by Audit Committee on 10.02.14 and approved by the Board in its meeting held on even date i.e. 11.02.14 and further limited reviewed by the Statutory Auditors of the Company.
- The company is exclusively in the pharmaceutical business segment.
- Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period.
- The above financial results are on stand alone basis.

By Order of the Board of Directors
of Nectar Lifesciences Limited

Sd/-
(Dinesh Dua)

Chief Executive Officer & Director

Certified to be true copy
For NECTAR LIFESCIENCES LIMITED

Sunder Lal
Company Secretary

Dated: 11.02.2014
Place: Chandigarh